Start your patients
on a convenient,
once daily treatment
Start your patients
on a convenient,
once daily treatment
Start your patients
on a convenient,
once daily treatment
VERQUVO provides a straight forward dose adjustment schedule to achieve the desired 10mg target dose.
- Start at 2.5mg once dailytaken with food.
- Double dose approximately every 2 weeks, as tolerated.
- Until the target maintenance dose of 10mg once dailyis achieved.
- Dose adjustment can be achieved in four weeks, but for some patients up-titration may take longer.
Importantly, no dosage adjustment of VERQUVO is required for patients with renal impairment (eGFR ≥ 15 mL/min/1.73m2, without dialysis).
This means, VERQUVO can provide a solution for patients who have experienced a worsening heart failure (HF) event and can be used across a broad range of patients with chronic HF, regardless of background therapies.
A safety profile you can depend on
Adopt a treatment with a well-tolerated safety profile that can be used across a broad range of patients with chronic HF, regardless of background therapy.
VERQUVO is well tolerated in patients with chronic HF following a worsening HF event.
- Patients experienced a low rate of symptomatic hypotension. The rates are comparable to placebo (VERQUVO 9.1% vs. Placebo 7.9%).
- Consistent safety profile in patients with Type 2 Diabetes, impaired renal function (eGFR > 15mL/min/1.73m2), atrial fibrillation and coronary heart disease, as well as in patients who have been treated with other HF therapies.
- Almost 95% of patients stayed on the therapy throughout the study duration.
- Discontinuation rates: VERQUVO 6.8% vs. placebo 6.1%.
Verquvo® delivered a safety profile comparable to the placebo arm
